Methods: We conducted a clinical trial in 390 adults with PTB in Ulaanbaatar, Mongolia, who were randomized to receive four biweekly doses of 3.5 mg (140,000 IU) vitamin D 3 (n = 190) or placebo (n = 200) during intensive-phase antituberculosis treatment.
Vitamin D was used to treat pulmonary tuberculosis (PTB) in the preantibiotic era (1) . Its major circulating metabolite,
25-hydroxyvitamin D (25[OH]D), supports
innate antimicrobial immune responses, suggesting a potential mechanism by which adjunctive vitamin D might enhance response to antituberculous therapy (2) . With one exception (3), randomized controlled trials (RCTs) evaluating effects of vitamin D supplementation on sputum culture conversion during intensive-phase therapy have not demonstrated effects on this outcome (4) (5) (6) (7) . However, these trials are variously limited by low prevalence of vitamin D deficiency in the study population at baseline, modest or unmeasured 25(OH)D response to supplementation, significant loss to followup, and low statistical power. Moreover, no trial conducted to date has investigated the influence of mutations in genes other than that encoding the vitamin D receptor (VDR) on responses to vitamin D supplementation in PTB, despite evidence that single nucleotide polymorphisms (SNPs) in other genes in the vitamin D pathway influence disease outcomes (8) . We therefore conducted an RCT that was powered to detect a modest effect of highdose vitamin D on time to sputum culture conversion in a population where profound deficiency was highly prevalent, with prespecified subgroup analysis to evaluate the effect of 36 SNPs in 11 vitamin D pathway genes on the response to vitamin D supplementation. Some of the results of this study have been previously reported in the form of abstracts (9, 10) .
Methods Study Design
We conducted a two-arm parallel doubleblind randomized placebo-controlled trial in the tuberculosis clinic at the National Center for Communicable Disease in Ulaanbaatar, Mongolia. The study was approved by the Ethics Review Board of the Mongolian Ministry of Health and the Office of Human Research Administration, Harvard School of Public Health (reference 19435). The trial was registered with ClinicalTrials.gov (NCT01657656).
Participants
Adults with newly diagnosed PTB and acidfast bacilli (AFB) visible on sputum smear microscopy were assessed for eligibility to participate. Principal exclusion criteria were age younger than 18 years and serum corrected calcium concentration greater than 2.65 mmol/L; full details of eligibility criteria are presented in the online supplement. Written informed consent was obtained from all participants before enrolment.
Randomization and Masking
Patients were randomly assigned to receive either four oral doses of 3.5 mg (140,000 IU) vitamin D 3 (each dose given as four tablets each containing 875 mg [35,000 IU] vitamin D 3 ) or placebo (each dose given as four placebo tablets of identical appearance and taste to active study medication), with a one-to-one allocation ratio. Active and placebo tablets were manufactured by Tishcon Corp., Westbury, NY. Full details of randomization methods are presented in the online supplement. Treatment allocation was concealed from patients and study staff. Those analyzing the data were not masked to group assignment.
Procedures
All participants initially received intensivephase antimicrobial therapy comprising isoniazid, rifampicin, pyrazinamide, and ethambutol. Those who were subsequently found to have a multidrug-resistant (MDR) isolate were switched from first-line therapy to an appropriate MDR TB treatment regimen according to the World Health Organization MDR TB guideline that was extant at the time of the study (11) . The first dose of study medication was administered within 2 days of starting antimicrobial treatment, and subsequent doses were administered at 2, 4, and 6 weeks after the start of antimicrobial treatment. Study medication was discontinued if participants withdrew consent to participate in the study, if they discontinued anti-TB treatment, if they were unable to provide a sputum sample, or if they developed druginduced liver injury or hypercreatininemia. After completion of 8 weeks of antimicrobial therapy, participants were discharged from the study, and continuation-phase antimicrobial therapy was initiated.
Participants completed a baseline clinical assessment including chest radiography; measurement of height, weight, and mid-upper arm circumference; and triceps, biceps, and subscapular skinfold thicknesses. Chest radiographs were read independently by two radiologists who were blinded to participant allocation; presence versus absence of cavities was recorded, along with the number of lung zones affected (nine zones per lung). Body mass index (BMI) was calculated using the formula: BMI = weight (kg)/[height (m)] 2 . We also collected a sputum sample for microscopy and culture, a urine sample for determination of urinary calcium:creatinine ratio, and a blood sample for DNA extraction and genotyping and determination of full blood count, erythrocyte sedimentation rate (ESR), and serum concentrations of calcium, albumin, C-reactive protein (CRP), and 25(OH)D. Participants were reviewed at 2, 4, 6, and 8 weeks after starting antituberculous therapy to assess clinical status and to monitor for adverse events. At each time point, a sputum specimen was collected from all patients who were able to expectorate spontaneously, weight and skin-fold 
Outcomes
The primary outcome of the study was time from initiation of antituberculous therapy to sputum culture conversion, estimated as the midpoint between the last positive sputum culture and the first negative sputum culture thereafter. Participants who were unable to expectorate spontaneously were deemed to be culture negative. Where participants were culture positive at their last follow-up (either at 8 weeks or earlier if lost to follow-up), time to sputum culture conversion was attributed as the number of days from the date of treatment initiation to the date of the last follow-up visit, and the censor variable was assigned a zero value to indicate that the endpoint of sputum culture conversion was not achieved. Secondary outcomes were the proportion of participants with negative sputum culture at 8 weeks; time from initiation of antituberculous therapy to sputum smear conversion (estimated as the midpoint between the last positive sputum smear and the first negative sputum smear thereafter); mean number of zones affected on chest radiograph at 8 weeks; mean serum concentrations of 25(OH)D, corrected calcium, CRP, and albumin; mean ESR, total white blood cell count, neutrophil count, monocyte count, and lymphocyte:monocyte ratio in peripheral blood; and mean BMI, mid-upper arm circumference, triceps skinfold thickness, and scapular skin-fold thickness. Safety was assessed by monitoring incidence of all serious adverse events (including deaths) and nonserious adverse events potentially related to the intervention (hypercalcemia and hypercalciuria).
Sample Size and Statistical Analysis
Assuming a median time to sputum culture conversion of 7 weeks in the control group, a follow-up period of 8 weeks, and accrual time of 2 years, we calculated that a total of 278 patients (139 patients in each group) would need to be recruited to detect a 2-week difference in median time to culture conversion between intervention and control groups with 80% power using a twosided test at the 5% significance level (12) . This number was increased by 25% to compensate for potential loss to follow-up, giving an original target sample size of 348. An additional 42 participants were enrolled for investigation of additional immunological outcomes, bringing total sample size to 390. Efficacy analysis was by intention to treat. All participants who took at least one dose of study medication were included in the safety analysis. One prespecified interim analysis at 12 months was performed by members of the Data Safety and Monitoring Board to test the effect of allocation on the primary outcome and incidence of serious adverse events. The Board recommended that the trial should continue, and results were not shared with investigators.
Analyses were performed using the STATA/IC (version 12.1, 2012; College Station, TX) software package. Significance was tested at the 5% level. The primary analysis for effect of allocation on time to sputum culture conversion was conducted using a Cox proportional hazards regression model adjusted for presence versus absence of cavitation on baseline chest radiograph (the stratification factor). A prespecified secondary analysis also adjusted for factors associating with delayed sputum culture conversion on univariate analysis with P , 0.20 (see Table E1 in the online supplement): age, sex, baseline sputum smear (,100 vs. >100 AFB per 100 high-power fields), drug-sensitivity profile (MDR TB vs. not), current smoking (yes vs. no), and current alcohol use (yes vs. no). Time to sputum smear conversion was similarly analyzed. The proportion of participants with sputum culture conversion at 8 weeks was analyzed with logistic regression adjusted for the factors listed above. Continuous outcome measures assessed at baseline and 2-weekly intervals thereafter were analyzed using linear regression adjusted for the factors listed above with random effects of individual, constrained so that there was no treatment effect at baseline, and with a treatment effect estimated at each subsequent time point. A P value for allocation-time interaction was used to evaluate evidence for an effect of allocation; where evidence was found (P , 0.05), adjusted effect estimates with 95% confidence intervals (CIs) at individual time points are reported. Subgroup analyses were performed by repeating primary efficacy analyses with the inclusion of the appropriate interaction term. Interaction effects were summarized as a ratio of hazard ratios (HRs) with 95% CI and P value. The Benjamini-Hochberg procedure for multiple-testing correction was applied to genetic analyses to control the false discovery rate at 20% (13) .
Results

Participant Flow and Recruitment
Participant flow is illustrated in Figure 1 . A total of 456 patients were assessed for eligibility to participate in the trial between October 31, 2012 and March 21, 2014: 66 were ineligible and 390 were randomized, of whom 190 were allocated to vitamin D and 200 were allocated to placebo. The trial ended on the date of the final study visit of the last participant to be randomized. All randomized participants received at least one dose of study medication and were included in the intention-to-treat analysis.
Baseline Characteristics
Participants' clinical and demographic characteristics were comparable for intervention versus control groups at baseline ( Table 1 Table 2 ). The HR for effect of allocation on time to sputum culture conversion, adjusted for presence versus absence of cavitation on baseline chest radiograph in the Cox regression model, was 1.09 (95% CI, 0.86-1.36; P = 0.48).
Male sex, age greater than or equal to the median value of 34 years, presence of cavitation on baseline chest radiograph, presence of greater than 100 AFB per 100 high-power fields on baseline sputum smear, presence of MDR isolate, current cigarette smoking (any vs. none), and current alcohol intake (any vs. none) were associated with delayed sputum culture conversion on univariate analysis, with P , 0.20 (Table E1 ). The HR for effect of allocation on time to sputum culture conversion after adjustment for all of these factors in the Cox regression model was 1.11 (95% CI, 0.88-1.39; P = 0.39; Table 2 ).
Secondary Outcomes, Efficacy
Results from analysis of secondary efficacy outcomes are presented in Table 2 . Allocation to vitamin D versus placebo did not influence the proportion of participants with sputum culture conversion at 8 weeks (150 of 190 vs. 148 of 200, respectively; adjusted odds ratio, 1.47; 95% CI, 0.88-2.45; P = 0.14). Vitamin D did, however, accelerate sputum smear conversion (adjusted HR, 1.47; 95% CI, 1.09-1.98; P = 0.01; Figure 2B ) and radiographic resolution (mean number of zones affected on chest radiograph at 8 weeks, 5.48 in intervention arm vs. 5.69 in placebo arm; 95% CI for difference, 0.06-0.77 zones; P = 0.02). The regimen of vitamin D administered in the trial was highly effective in correcting vitamin D deficiency in the intervention arm: mean serum 25(OH)D concentration at 8 weeks was 154.5 nmol/L in the intervention arm of the study versus 15.2 nmol/L in the control arm (95% CI for difference, 125.9-154.7 nmol/L; P , 0.001). Allocation to the intervention arm of the study also induced an increase in mean serum corrected calcium concentration and mean urinary calcium:creatinine ratio from the 2-week time point onward (P , 0.001).
No consistent effect of vitamin D supplementation was seen on serum concentrations of the acute-phase reactants CRP, albumin, or ESR. However, administration of vitamin D reduced total white blood cell counts, neutrophil counts, and monocyte counts and elevated lymphocyte:monocyte ratios in peripheral blood.
No clinically significant effect of vitamin D was seen on anthropometric outcomes.
Subgroup Analyses
Results of subgroup analyses are presented in 
Discussion
To our knowledge, this study is the largest RCT to investigate effects of adjunctive vitamin D supplementation on the outcome of sputum culture conversion in patients with PTB to be performed to date. It is also the only such study to comprehensively investigate the influence of genetic variation in the vitamin D pathway on PTB patients' response to adjunctive vitamin D. In the study population as a whole, adjunctive vitamin D did not influence time to sputum culture conversion (the primary outcome), despite accelerating sputum smear conversion and exerting favorable immunomodulatory actions. No deaths occurred in the intervention arm, but five deaths occurred in the placebo arm. Our genetic analysis identified novel variants in VDR and CYP27B1 that modified the effect of the intervention: adjunctive vitamin D accelerated sputum culture conversion in patients carrying one or more minor alleles of these SNPs but not in those homozygous for the major alleles. Our null finding with respect to the outcome of sputum culture conversion is consistent with those of other trials in the field conducted by ourselves (4) and others (5-7), with one exception (3). We also replicated previous findings that adjunctive vitamin D exerted antiinflammatory actions (accelerating resolution of peripheral blood neutrophilia) and boosted the lymphocyte: monocyte ratio in peripheral blood (14) . The latter marker has been identified as a biomarker of resolution of pulmonary inflammation in an animal model of TB (15) . Taking these findings together (17) (18) (19) . Might subgroups of patients derive a benefit from high-dose adjunctive vitamin D? Among patients with MDR TB, 5 of 13 patients receiving adjunctive vitamin D experienced sputum culture conversion at 8 weeks, as compared with 0 of 8 such patients randomized to adjunctive placebo (P = 0.11; Fisher exact test). This finding echoes the trend toward improved outcomes with adjunctive vitamin D in patients with MDR TB reported by Tukvadze and colleagues (7). Neither trial was individually powered to explore the effects of adjunctive vitamin D in patients with MDR TB, but the hypothesis that a host-directed therapy may be more efficacious in the context of disease that is less responsive to antimicrobials is plausible. Taken together, these findings suggest that a trial of adjunctive vitamin D in patients with MDR TB may be justified.
Another possibility is that subgroups of patients with particular mutations in genes in the vitamin D pathway may have enhanced responsiveness to adjunctive vitamin D. We have previously reported that patients homozygous for the minor allele of the TaqI VDR polymorphism had enhanced responsiveness to vitamin D (4). This finding was not replicated in the current study, possibly due to lack of power associated with the relatively low frequency of the minor allele of this polymorphism in Mongolia versus the study population in London (10.6 vs. 31.3%, respectively). We did, however, identify two other SNPs in VDR (rs4334089 and rs11568820) and-for the first time-one SNP in CYP27B1 (rs4646536) that significantly modified the effect of vitamin D on sputum culture conversion after correction for multiple comparisons. CYP27B1 governs conversion of 25(OH)D to the active metabolite 1,25-dihydroxyvitamin D, whereas VDR is the cognate receptor for this metabolite that mediates its influence on expression of more than 200 genes (20) . It is therefore biologically plausible that polymorphisms in these two genes could modify effects of vitamin D supplementation-a hypothesis strengthened by reports of associations between these polymorphisms and diverse health outcomes (8) .
Our study has several strengths. Time to sputum culture conversion was the primary outcome: this is a recognized surrogate for treatment failure and relapse (21) . We were well-powered to detect a relatively modest effect of adjunctive vitamin D therapy: the study population had very low vitamin D status at baseline; administration of study medication was directly observed, assuring excellent adherence; and the regimen used in the active arm of the trial effectively elevated serum 25(OH)D concentrations into the high physiological range. Our genetic analysis was comprehensive, in that it explored the influence of variation in a total of 11 different genes in the vitamin D pathway; previous studies testing for genetic effect modification have only investigated polymorphisms in VDR (4, 7).
Our study also has some limitations. It was not powered to detect subgroup effects: null results of some subgroup analyses may therefore be attributable to type 2 error. We used an intermittent bolus dosing regimen to optimize adherence and correct vitamin D deficiency rapidly. There is some evidence to suggest that daily or weekly regimens of vitamin D supplementation may be optimal in enhancing host responses to respiratory pathogens (22) ; however, our finding that leukocyte counts differed between arms at follow-up indicates that the dosing regimen was effective in modulating the host response.
In conclusion, this large study used a high dose of vitamin D in a population with very low baseline vitamin D status but found no effect of this intervention on time to sputum culture conversion in the study population as a whole. Taken together with null results from other trials in the field for the outcome of sputum culture conversion, it seems unlikely that further such trials in patients with drug-sensitive disease will yield positive results. It is possible that the intervention may provide benefit in particular subgroups, such as those with MDR TB and individuals who have particular mutations in genes encoding the vitamin D receptor and the 25(OH)D 1a-hydroxylase enzyme; meta-analysis of individual participant data from these trials is ongoing (23) , which will provide enhanced power to test these hypotheses. n Hazard ratio from Cox regression, adjusting for age, sex, presence/absence of cavitation on baseline chest radiograph, baseline sputum smear (,100 vs. >100 AFB per 100 high-powered fields), drug-sensitivity profile (MDR vs. non-MDR), current smoking (yes vs. no), and current alcohol use (yes vs. no). ‡ From Cox regression using the whole sample and including an interaction between subgroup and allocation, adjusting for age, sex, presence/absence of cavitation on baseline chest radiograph, baseline sputum smear (,100 vs. >100 AFB per 100 high-powered fields), drug-sensitivity profile (MDR vs. non-MDR), current smoking (yes vs. no), and current alcohol use (yes vs. no).
x The HR for effect of allocation on time to sputum culture conversion in participants with MDR TB could not be calculated, because 0 of 8 participants in this subgroup who were allocated to placebo experienced sputum culture conversion during the trial. jj The HR ratio and corresponding P value could not be calculated because the HR for effect of allocation within the MDR subgroup could not be calculated (see previous footnote). ¶ Per-protocol completion defined as completing trial having taken all doses of study medication. **These P values remained significant when controlling the false discovery rate at 20% using a Benjamini-Hochberg procedure.
